Jonathan Benassaya remembers the melanoma diagnosis vividly. It arrived in 2020, during the first year of the pandemic, when the former Deezer CEO had plenty of time to contemplate mortality and what he'd do if he got a second chance. Less than two years after incorporating SkinBit, he's placed his bet: a startup building an AI-powered scanner meant to catch skin cancer before it requires a biopsy.
Last October, Benassaya closed a $4,081,321 crowdfunding campaign on Wefunder. Seven hundred twenty-six investors participated, according to Wefunder's investor panel, including one who wrote a $100,000 lead check—a respectable haul by crowdfunding standards. The company has also mentioned raising a "$6 million pre-seed round," though no independent source has confirmed it and the figure doesn't appear in public SEC filings or press releases. The verified capital raised stands at just over $4 million from crowdfunding.
What has surfaced is ambition. The Delaware-incorporated company filed an SEC Form C in June 2025, authorizing a maximum offering of up to $5 million under Regulation Crowdfunding via a SAFE note. The pitch centers on a device called Sentinel: a full-body scanner using millimeter-wave imaging to create what the company calls a digital skin "twin." Scans supposedly take under a minute and deliver "20% higher accuracy than current methods," according to marketing materials. Whether those claims hold up under clinical scrutiny is another matter—peer-reviewed studies and regulatory filings remain notably absent.
The Technology Gambit
Millimeter-wave radar isn't new. It's been used in airport security scanners for years. SkinBit's wager is that the same technology can peer beneath the skin's surface to spot lesions invisible to the naked eye or even traditional dermatoscopes.
The company claims exclusive licensing agreements with Stevens Institute of Technology for sub-surface imaging patents. Stevens does hold relevant patents in millimeter-wave skin imaging and has published research on handheld device prototypes, but the actual licensing arrangement is company-claimed, with no public document tying SkinBit to Stevens in a verifiable way. It's the kind of detail that matters when you're asking patients—or investors—to trust a medical device.
Internal testing, according to a 2025 blog post, suggests 93% sensitivity and 97% specificity across 50,000 lesions. Those are impressive numbers. They're also unvalidated by outside researchers, which means they're essentially marketing claims until proven otherwise.
The prototype was originally slated for "summer 2025" readiness. The company's marketing materials now reference "SkinBit locations," though no independently verified clinic addresses or opening announcements have materialized. Perhaps the timeline slipped. Early-stage hardware startups rarely ship on schedule, particularly when navigating FDA processes.
A Team With Credentials, If Not Yet Clearance
Benassaya didn't walk into this alone. He assembled a team with genuine pedigree. Dr. Justin Ko, a Clinical Professor of Dermatology and Medical Director at Stanford Health Care, signed on as co-founder and medical advisor. Bill Dower, the CTO, spent years at Raytheon working on radar and synthetic aperture radar systems before jumping to startups. Manuel Colom, who handles design, previously worked at Apple. Radek Grzeszczuk leads computer vision after two decades in the field.
On paper, it's the kind of roster that catches venture capitalists' attention. The question is whether the team can translate expertise into regulatory approval and commercial traction.
Navigating a Crowded, Regulated Landscape
SkinBit is hardly alone in chasing AI-powered skin cancer detection. The difference is that some competitors have already cleared regulatory hurdles.
DermaSensor, for instance, received FDA De Novo clearance in January 2024 for its AI-enabled handheld device using elastic-scattering spectroscopy. Physicians can use it on suspicious lesions during routine exams. In the UK, Skin Analytics' DERM platform earned a conditional recommendation from the National Institute for Health and Care Excellence in 2025 and is being deployed across NHS pathways with CE Class III marking.
SkinBit, by contrast, has no FDA filings or clearances on record. That's not unusual for a company incorporated in October 2024—barely a year old when the crowdfunding round wrapped—but it does highlight the distance between prototype and product. The FDA doesn't hand out De Novo clearances lightly, especially for devices claiming to detect cancer.
The company's materials reference "clinical-grade imaging validated by dermatologists," but validation and regulatory clearance are different beasts. One involves testing under controlled conditions. The other involves convincing federal regulators that your device is safe and effective for public use.
The Market Opportunity Is Real. The Execution Risk Is, Too.
Benassaya isn't wrong about the need. Skin cancer incidence provides genuine tailwinds. The American Cancer Society estimates roughly 5.4 million basal and squamous cell skin cancers are diagnosed annually in the U.S. The CDC reports 6.1 million people treated each year for skin cancers, with medical costs hitting $8.9 billion annually. Physician shortages compound the problem—the Association of American Medical Colleges projects significant gaps through 2030, though the supporting data for SkinBit's claim of "50% unmet dermatology need" remains unverified.
Still, demand and opportunity don't guarantee success, particularly in medical devices. The path from crowdfunding to commercial deployment involves clinical trials, regulatory submissions, manufacturing scale-up, reimbursement negotiations with insurers, and physician adoption. Each step carries risk.
What the Numbers Actually Show
The SEC filing paints a picture of an extremely early-stage company. Zero employees listed. Four hundred sixty-seven dollars in total assets at the most recent fiscal year-end. An offering deadline of April 30, 2026. All typical for a nascent filer, but hardly the profile of a company ready to deploy scanners in clinics.
SkinBit's Wefunder page listed proceeds earmarked for R&D, AI integration, clinical testing tools, regulatory compliance, clinic deployment, marketing, and working capital—standard buckets for an early-stage medical device play. KingsCrowd's 2025 snapshot pegged the campaign valuation at $20 million, though that figure reflects crowdfunding terms rather than an independent valuation.
The Bet on Millimeter Waves
Whether SkinBit can translate crowdfunding momentum into FDA clearance and commercial traction remains an open question. For now, the verified capital stands at just over $4 million. Not nothing, but also not enough to shepherd a Class III medical device through the full regulatory gauntlet without additional funding.
Benassaya's personal story carries weight. Melanoma survivors understand, in a way most people don't, the terror of waiting for biopsy results. If millimeter-wave imaging can catch cancer earlier—truly earlier, in a way validated by clinical trials and regulatory review—it could save lives.
But personal conviction doesn't clear FDA hurdles. The next chapter for SkinBit will be written in clinical data, regulatory filings, and the slow, grinding work of proving that a promising idea can become a safe, effective medical device. The melanoma survivor's bet is on the table. Now comes the hard part.
